A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care (ISABELA1)
Diseases of the Lung | Diseases of the Respiratory Systems
What is the purpose of this trial?
The main purpose of this study is to see how GLPG1690 works together with your current standard treatment on your lung function and IPF disease in general. The study will also investigate how well GLPG1690 is tolerated (for example if you get any side effects while on study drug).
- Ages40 years and older
- Trial withGALAPAGOS NV (US)
- Start Date05/29/2019
- End Date12/30/2021
- Last Updated07/01/2019
- Study HIC#2000025140